Genome-wide gene expression profiling of formalin-fixed paraffin-embedded breast cancer core biopsies using microarrays

Journal of Histochemistry and Cytochemistry

Volumn 59, Issue 2, 2011, Pages 146-157

  Budczies, Jan ^a   Weichert, Wilko ^a   Noske, Aurelia ^a   Müller, Berit Maria ^a   Weller, Claudia ^b   Wittenberger, Timo ^b   Hofmann, Hans Peter ^b   Dietel, Manfred ^a   Denkert, Carsten ^a   Gekeler, Volker ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Nycomed GmbH   (Germany)

Author keywords

Breast cancer; Core needle biopsies; Dna microarray; Formalin fixed paraffin embedded samples; Gene expression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN; ESTROGEN RECEPTOR ALPHA; HER2 PROTEIN, HUMAN; RNA;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CORRELATION ANALYSIS; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; NEEDLE BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; BREAST TUMOR; CLUSTER ANALYSIS; FEASIBILITY STUDY; GENETICS; HUMAN GENOME; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; NUCLEIC ACID HYBRIDIZATION; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRINCIPAL COMPONENT ANALYSIS; QUALITY CONTROL; TISSUE FIXATION;

BIOPSY, NEEDLE; BREAST NEOPLASMS; CLUSTER ANALYSIS; ESTROGEN RECEPTOR ALPHA; FEASIBILITY STUDIES; FORMALDEHYDE; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAFFIN EMBEDDING; PHENOTYPE; POLYMERASE CHAIN REACTION; PRINCIPAL COMPONENT ANALYSIS; QUALITY CONTROL; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RNA; TISSUE FIXATION;

EID: 79953776636     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.2010.956607     Document Type: Article

References (41)

1. April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, Izzo J, Cox D, Jones W, Rubio R, Holton K, et al. 2009. Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS ONE. 4:e8162.
2. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu M, Rowley SC, Shak S, Perez EA, Shulman LJ, et al. 2008. Estrogenand progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 26:2473-2481.
3. Bibikova M, Chudin E, Arsanjani A, Zhou L, Garcia EW, Modder J, Kostelec M, Barker D, Downs T, Fan J, et al. 2007. Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics. 89:666-672.
4. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, et al. 2006. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 98:1183-1192.
5. Coudry RA, Meireles SI, Stoyanova R, Cooper HS, Carpino A, Wang X, Engstrom PF, Clapper ML. 2007. Successful application of microarray technology to microdissected formalinfixed, paraffin-embedded tissue. J Mol Diagn. 9:70-79.
6. Ein-Dor L, Kela I, Getz G, Givol D, Domany E. 2005. Outcome signature genes in breast cancer: is there a unique set? Bioinformatics. 21:171-178.
7. Elston CW, Ellis IO. 2002. Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 41:154-161.
8. Farragher SM, Tanney A, Kennedy RD, Paul Harkin D. 2008. RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol. 130:435-445.
9. Fedorowicz G, Guerrero S, Wu TD, Modrusan Z. 2009. Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas. BMC Med Genomics. 2:23.
10. Frank M, Döring C, Metzler D, Eckerle S, Hansmann M. 2007. Global gene expression profiling of formalin-fixed paraffin-embedded tumor samples: a comparison to snap-frozen material using oligonucleotide microarrays. Virchows Arch. 450: 699-711.
11. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JEJ, et al. 2007. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 8:203-211.
12. Gruvberger S, Ringnér M, Chen Y, Panavally S, Saal LH, Borg A, Fernö M, Peterson C, Meltzer PS. 2001. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61:5979-5984.
13. Hlubek F, Brabletz T, Budczies J, Pfeiffer S, Jung A, Kirchner T. 2007. Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. Int J Cancer. 121: 1941-1948.
14. Iverson AA, Gillett C, Cane P, Santini CD, Vess TM, Kam-Morgan L, Wang A, Eisenberg M, Rowland CM, Hessling JJ, et al. 2009. A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens. J Mol Diagn. 11:117-130.
15. Järvinen TAH, Liu ET. 2003. Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer-more common than anticipated. Cytopathology. 14:309-313.
16. Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statistics, 2010. CA Cancer J Clin. 60:277-300.
17. Kauraniemi P, Kallioniemi A. 2006. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer. 13:39-49.
18. Klur S, Toy K, Williams MP, Certa U. 2004. Evaluation of procedures for amplification of small-size samples for hybridization on microarrays. Genomics. 83:508-517.
19. Linton K, Hey Y, Dibben S, Miller C, Freemont A, Radford J, Pepper S. 2009. Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays. Biotechniques. 47:587-596.
20. Linton KM, Hey Y, Saunders E, Jeziorska M, Denton J, Wilson CL, Swindell R, Dibben S, Miller CJ, Pepper SD, et al. 2008. Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours. Br J Cancer. 98:1403-1414.
21. Ma X, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG. 2006. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 24:4611-4619.
22. Moasser MM. 2007. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 26:6469-6487.
23. Müller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, Weichert W, Winzer KW, Kristiansen G, Petry C, et al. 2010. Quantitative determination of estrogen receptor, progesterone receptor andHER2 mRNA in formalin-fixed paraffin-embedded tissue: a new option forpredictive biomarker assessment in breast cancer. Diagn Mol Pathol. In press.
24. Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, Asmann YW, Klee GG, Ballman KV, Jenkins RB. 2008. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS ONE. 3:e2318.
25. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J Clin. 55:74-108.
26. Penland SK, Keku TO, Torrice C, He X, Krishnamurthy J, Hoadley KA, Woosley JT, Thomas NE, Perou CM, Sandler RS, et al. 2007. RNA expression analysis of formalin-fixed paraffinembedded tumors. Lab Invest. 87:383-391.
27. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. 2000. Molecular portraits of human breast tumours. Nature. 406:747-752.
28. Ravo M, Mutarelli M, Ferraro L, Grober OMV, Paris O, Tarallo R, Vigilante A, Cimino D, De Bortoli M, Nola E, et al. 2008. Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays. Lab Invest. 88:430-440.
29. Remmele W, Stegner HE. 1987. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue [in German]. Pathologe. 8:138-140.
30. Ribeiro-Silva A, Zhang H, Jeffrey SS. 2007. RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: a comparison of column purification and magnetic bead-based technologies. BMC Mol Biol. 8:118.
31. Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, et al. 2007. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 16:86-93.
32. Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, et al. 2006. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Zentralbl Gynakol. 128:76-81.
33. Rody A, Karn T, Solbach C, Gaetje R, Munnes M, Kissler S, Ruckhäberle E, Minckwitz GV, Loibl S, Holtrich U, et al. 2007. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast. 16:235-240.
34. Ross JS. 2009. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv Anat Pathol. 16:204-215.
35. Schmitz KJ, Grabellus F, Callies R, Otterbach F, Wohlschlaeger J, Levkau B, Kimmig R, Schmid KW, Baba HA. 2005. High expression of focal adhesion kinase (p125FAK) in nodenegative breast cancer is related to overexpression of HER-2/ neu and activated Akt kinase but does not predict outcome. Breast Cancer Res. 7:R194-R203.
36. Scicchitano MS, Dalmas DA, Bertiaux MA, Anderson SM, Turner LR, Thomas RA, Mirable R, Boyce RW. 2006. Preliminary comparison of quantity, quality, and microarray performance of RNA extracted from formalin-fixed, paraffin-embedded, and unfixed frozen tissue samples. J Histochem Cytochem. 54:1229-1237.
37. Srivastava PK, Küffer S, Brors B, Shahi P, Li L, Kenzelmann M, Gretz N, Gröne H. 2008. A cut-off based approach for gene expression analysis of formalin-fixed and paraffin-embedded tissue samples. Genomics. 91:522-529.
38. Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Børresen-Dale A. 2006. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 7:127.
39. Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C. 2007. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol. 19:552-557.
40. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530-536.
41. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al. 2007. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 131:18-43.